DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
INCLISIRAN SODIUM
Search structure
Synonyms:
ALN-60212 SODIUM
ALN-PCSSC SODIUM
LEQVIO
LEQVIO SODIUM
Status:
Approved (2021)
Entry Type:
Unknown
Molecule Category:
UNKNOWN
Pharmacology
Action
Mechanism of Action
Reference
RNAI INHIBITOR
PCSK9 mRNA rnai inhibitor
Indications
Mesh Heading
Maximum Phase
Mesh ID
Reference
Atherosclerosis
4
D050197
FDA
Hyperlipoproteinemia Type II
4
D006938
FDA
CONTENTS
Structure
Indications
×
Active Pharmaceutical Ingredients (APIs)
Scaffolds
Exact
Similarity
SubStructure
Threshold (%) >=
70